SK287842B6 - Oxazole derivative, method for the preparation thereof and use, pharmaceutical compositions containing thereof - Google Patents

Oxazole derivative, method for the preparation thereof and use, pharmaceutical compositions containing thereof Download PDF

Info

Publication number
SK287842B6
SK287842B6 SK1385-2003A SK13852003A SK287842B6 SK 287842 B6 SK287842 B6 SK 287842B6 SK 13852003 A SK13852003 A SK 13852003A SK 287842 B6 SK287842 B6 SK 287842B6
Authority
SK
Slovakia
Prior art keywords
methyl
ethoxy
phenyl
oxazol
propionic acid
Prior art date
Application number
SK1385-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK13852003A3 (en
Inventor
Alfred Binggeli
Markus Boehringer
Uwe Grether
Hans Hilpert
Hans-Peter Maerki
Markus Meyer
Peter Mohr
Fabienne Ricklin
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SK13852003A3 publication Critical patent/SK13852003A3/sk
Publication of SK287842B6 publication Critical patent/SK287842B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1385-2003A 2001-05-15 2002-05-06 Oxazole derivative, method for the preparation thereof and use, pharmaceutical compositions containing thereof SK287842B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111745 2001-05-15
PCT/EP2002/004962 WO2002092084A1 (en) 2001-05-15 2002-05-06 Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes

Publications (2)

Publication Number Publication Date
SK13852003A3 SK13852003A3 (en) 2004-10-05
SK287842B6 true SK287842B6 (sk) 2011-12-05

Family

ID=8177436

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1385-2003A SK287842B6 (sk) 2001-05-15 2002-05-06 Oxazole derivative, method for the preparation thereof and use, pharmaceutical compositions containing thereof

Country Status (38)

Country Link
US (1) US6642389B2 (cg-RX-API-DMAC10.html)
EP (1) EP1392295B1 (cg-RX-API-DMAC10.html)
JP (2) JP4330883B2 (cg-RX-API-DMAC10.html)
KR (1) KR100654516B1 (cg-RX-API-DMAC10.html)
CN (1) CN100356917C (cg-RX-API-DMAC10.html)
AR (1) AR035892A1 (cg-RX-API-DMAC10.html)
AT (1) ATE327753T1 (cg-RX-API-DMAC10.html)
AU (1) AU2002342244B2 (cg-RX-API-DMAC10.html)
BG (1) BG66316B1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0209821B1 (cg-RX-API-DMAC10.html)
CA (1) CA2445145C (cg-RX-API-DMAC10.html)
CY (1) CY1105160T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ20033037A3 (cg-RX-API-DMAC10.html)
DE (1) DE60211891T2 (cg-RX-API-DMAC10.html)
DK (1) DK1392295T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP034848A (cg-RX-API-DMAC10.html)
EG (1) EG25755A (cg-RX-API-DMAC10.html)
ES (1) ES2264482T3 (cg-RX-API-DMAC10.html)
GT (1) GT200200085A (cg-RX-API-DMAC10.html)
HR (1) HRP20030889B1 (cg-RX-API-DMAC10.html)
HU (1) HU230224B1 (cg-RX-API-DMAC10.html)
IL (2) IL158589A0 (cg-RX-API-DMAC10.html)
JO (1) JO2282B1 (cg-RX-API-DMAC10.html)
MA (1) MA27025A1 (cg-RX-API-DMAC10.html)
ME (1) ME01310B (cg-RX-API-DMAC10.html)
MX (1) MXPA03010435A (cg-RX-API-DMAC10.html)
MY (1) MY136761A (cg-RX-API-DMAC10.html)
NO (1) NO333833B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ529033A (cg-RX-API-DMAC10.html)
PA (1) PA8544901A1 (cg-RX-API-DMAC10.html)
PE (1) PE20021152A1 (cg-RX-API-DMAC10.html)
PL (1) PL208074B1 (cg-RX-API-DMAC10.html)
PT (1) PT1392295E (cg-RX-API-DMAC10.html)
RU (1) RU2278859C2 (cg-RX-API-DMAC10.html)
SI (1) SI1392295T1 (cg-RX-API-DMAC10.html)
SK (1) SK287842B6 (cg-RX-API-DMAC10.html)
WO (1) WO2002092084A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200308538B (cg-RX-API-DMAC10.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
IL152979A0 (en) * 2000-05-26 2003-06-24 Nippon Shinyaku Co Ltd Heterocyclic compounds
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
RU2278859C2 (ru) * 2001-05-15 2006-06-27 Ф.Хоффманн-Ля Рош Аг Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета
WO2003013571A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7259175B2 (en) 2002-02-25 2007-08-21 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
ATE483699T1 (de) * 2002-08-30 2010-10-15 Hoffmann La Roche Neue 2-arylthiazolverbindungen als ppar-alpha und gamma agonisten
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
JP2006514976A (ja) * 2002-11-15 2006-05-18 カディラ ヘルスケア リミティド 置換されているアラルキル誘導体
DE60323130D1 (de) * 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
FR2849849B1 (fr) 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7262303B2 (en) 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
RU2374230C2 (ru) 2003-11-05 2009-11-27 Ф.Хоффманн-Ля Рош Аг Фенильные производные в качестве ppar агонистов
KR100849352B1 (ko) 2003-11-05 2008-07-29 에프. 호프만-라 로슈 아게 Ppar 활성화제로서 벤조-융합된 화합물
WO2005056536A1 (en) * 2003-12-10 2005-06-23 Ranbaxy Laboratories Limited Antidiabetic agents which exhibit activity against ppar
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
MXPA06012683A (es) 2004-05-03 2007-01-16 Hoffmann La Roche Derivados de indolilo como moduladores de receptor x del higado.
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N-芳丙烯酰基取代的酪氨酸衍生物
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
WO2006108491A1 (en) * 2005-04-11 2006-10-19 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Improved process for preparing oxazole nitriles
US20060241073A1 (en) * 2005-04-20 2006-10-26 Wanders Ronaldus J A Means and methods for counteracting fatty acid accumulation
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
US20100063041A1 (en) * 2007-03-07 2010-03-11 Ho-Sang Moon Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
ES2390620T3 (es) * 2008-03-10 2012-11-14 Nestec S.A. Ácidos dicarboxílicos de cadena mediana y sus derivados y trastornos metabólicos
JP2011520890A (ja) * 2008-05-15 2011-07-21 メルク・シャープ・エンド・ドーム・コーポレイション オキサゾロベンゾイミダゾール誘導体
WO2010072386A2 (en) 2008-12-23 2010-07-01 Roche Diagnostics Gmbh Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof
CN102292074B (zh) * 2009-01-23 2013-08-21 霍夫曼-拉罗奇有限公司 包含阿格列扎的药物组合物
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8450496B2 (en) * 2009-03-24 2013-05-28 Hoffman-La Roche Inc. Process for the preparation of propionic acid derivatives
EP2585452B1 (en) 2009-12-07 2015-09-23 F.Hoffmann-La Roche Ag Process for the preparation of propionic acid derivatives
CN102351852B (zh) * 2011-08-23 2014-06-18 上海交通大学 苯并呋喃类化合物及其制备方法、用途
WO2013181384A1 (en) 2012-05-31 2013-12-05 Ratiopharm Gmbh Solid state forms of aleglitazar sodium
CA2879500A1 (en) * 2012-09-12 2014-03-20 F. Hoffmann-La Roche Ag Solid forms of (s)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid and of salts thereof
CN109588042A (zh) 2015-11-18 2019-04-05 豪夫迈·罗氏有限公司 用于治疗糖尿病肾病的阿格列扎
US20190350955A1 (en) 2016-06-30 2019-11-21 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of cardiomyopathies
WO2020156683A1 (en) 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
EP4384507A4 (en) * 2021-08-13 2025-06-18 Alebund Pharmaceuticals (Hong Kong) Limited Deuterated compounds
EP4615433A1 (en) 2022-11-08 2025-09-17 Genfit Ppar-alpha/gamma agonist for use in the treatment of liver failure
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011326A (en) 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
RU2032677C1 (ru) * 1992-05-05 1995-04-10 Бристоль-Мейерз Сквибб Компани Производные оксазола
SK695A3 (en) 1992-07-03 1995-07-11 Smithkline Beecham Plc Heterocyclic compounds method of their production and using
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
KR100499106B1 (ko) 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제
DE19711616A1 (de) * 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
ES2200248T3 (es) 1997-09-19 2004-03-01 Ssp Co., Ltd. Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen.
CN1208326C (zh) 1998-04-23 2005-06-29 雷迪实验室有限公司 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
EP1078923B1 (en) 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Process for the preparation of benzothiophene derivatives
DK1313716T3 (da) * 2000-08-23 2007-08-27 Lilly Co Eli Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister
RU2278859C2 (ru) * 2001-05-15 2006-06-27 Ф.Хоффманн-Ля Рош Аг Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета

Also Published As

Publication number Publication date
KR20030096397A (ko) 2003-12-24
RU2003134150A (ru) 2005-06-10
WO2002092084A1 (en) 2002-11-21
JP4330883B2 (ja) 2009-09-16
DE60211891T2 (de) 2007-05-24
EP1392295B1 (en) 2006-05-31
JO2282B1 (en) 2005-09-12
NO20035086L (no) 2003-11-14
HK1067534A1 (en) 2005-04-15
BG108362A (bg) 2005-03-31
CZ20033037A3 (cs) 2004-06-16
EG25755A (en) 2012-06-26
PL208074B1 (pl) 2011-03-31
HUP0400992A3 (en) 2007-11-28
ECSP034848A (es) 2003-12-24
PA8544901A1 (es) 2003-01-24
HUP0400992A2 (hu) 2004-08-30
IL158589A0 (en) 2004-05-12
HU230224B1 (hu) 2015-10-28
NO20035086D0 (no) 2003-11-14
CA2445145C (en) 2008-10-14
IL158589A (en) 2010-11-30
SK13852003A3 (en) 2004-10-05
HRP20030889A2 (en) 2005-08-31
AU2002342244B2 (en) 2005-06-16
ATE327753T1 (de) 2006-06-15
ME01310B (me) 2011-10-10
MY136761A (en) 2008-11-28
DK1392295T3 (da) 2006-10-02
CY1105160T1 (el) 2009-11-04
SI1392295T1 (sl) 2006-10-31
US6642389B2 (en) 2003-11-04
PL367087A1 (en) 2005-02-21
RU2278859C2 (ru) 2006-06-27
DE60211891D1 (de) 2006-07-06
BR0209821A (pt) 2004-06-01
HRP20030889B1 (hr) 2011-10-31
PT1392295E (pt) 2006-09-29
CA2445145A1 (en) 2002-11-21
EP1392295A1 (en) 2004-03-03
KR100654516B1 (ko) 2006-12-05
CN1509173A (zh) 2004-06-30
NZ529033A (en) 2005-06-24
GT200200085A (es) 2003-01-16
JP2009138011A (ja) 2009-06-25
JP2004529174A (ja) 2004-09-24
BG66316B1 (bg) 2013-04-30
ZA200308538B (en) 2005-04-26
ES2264482T3 (es) 2007-01-01
AR035892A1 (es) 2004-07-21
CN100356917C (zh) 2007-12-26
US20030055265A1 (en) 2003-03-20
NO333833B1 (no) 2013-09-30
PE20021152A1 (es) 2003-02-07
BRPI0209821B1 (pt) 2016-09-27
MXPA03010435A (es) 2004-03-09
MA27025A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
KR100654516B1 (ko) 당뇨병 치료에서 ppar-알파 및 -감마 활성제로서사용하기 위한 카복실산 치환된 옥사졸 유도체
AU2002342244A1 (en) Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes
JP4551222B2 (ja) Pparアゴニストとしての置換4−アルコキシオキサゾール誘導体
CA2499721C (en) Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists
RS50451B (sr) Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa-i-gama aktivatori u lečenju dijabetesa
HK1067534B (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20200506